Martin McMahon, PhD

Martin McMahon, PhD

Assistant Director of Professional Education; and Co-Leader, Developmental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center
Efim Guzik Distinguished Professorship in Cancer Biology, UCSF

Phone: (415) 502-5829 (voice)
Box 0128, UCSF
San Francisco, CA 94143-0128

View on UCSF Profiles

Cancer Center Membership

Program Member » Developmental Therapeutics

Additional Websites


University of Glasgow, Glasgow, Scotland, B.Sc., 1981, Biochemistry
University of London, London, England, Ph.D., 1985, Biochemistry

Professional Experience

  • 1989-1991
    Assistant Specialist, Hooper Foundation, University of California, San Francisco, CA.
  • 1991-1997
    Staff Scientist, Dept of Cell Signaling, DNAX Research Institute, Palo Alto, CA
  • 1997-1998
    Senior Staff Scientist, Dept. of Cell Signaling, DNAX Research Institute, Palo Alto, CA
  • 1998
    Associate Professor, University of California San Francisco, CA
  • 2001-present
    Efim Guzik Distinguished Professor of Cancer Biology, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2001-2007
    Co-Director, UCSF Biomedical Sciences Graduate Program
  • 2004-2006
    Co-Leader, UCSF Comprehensive Cancer Center Program in Liver Cancer
  • 2006-present
    Professor-In-Residence, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2007-2011
    Leader, UCSF Helen Diller Family Comprehensive Cancer Center Program in Pancreas Cancer
  • 2007-present
    Director of Professional Education, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2011-present
    Co-Leader, UCSF Helen Diller Family Comprehensive Cancer Center Program in Developmental Therapeutics

Honors & Awards

  • 1977-1981
    Imperial Chemical Industries (ICI) Undergraduate Educational Scholarship
  • 1981
    J. N. Davidson Memorial Prize in Biochemistry
  • 1981-1985
    ICI Graduate Student Bursary and Postgraduate Educational Scholarship
  • 1985-1987
    Imperial Cancer Research Fund Postdoctoral Traveling Fellowship
  • 1988-1990
    American Cancer Society (California Division) Senior Postdoctoral Fellowship
  • 2001
    NIH/NCI Pancreatic Cancer Progress Review Group (Panc CA PRG)
  • 2001
    Served on the National Cancer Legislative Action Committee
  • 2006
    Diana Ashby Award of the Melanoma Research Foundation
  • 2009-present
    Charter member of NIH BMCT study section

Selected Publications

  1. Mann MB, Black MA, Jones DJ, Ward JM, Yew CC, Newberg JY, Dupuy AJ, Rust AG, Bosenberg MW, McMahon M, Print CG, Copeland NG, Jenkins NA. Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma. Nat Genet. 2015 May; 47(5):486-95.
    View on PubMed
  2. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
    View on PubMed
  3. Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 Activation Blocks Braf(V600E)-Induced Growth Arrest but Is Insufficient for Melanoma Formation. Cancer Cell. 2015 Jan 12; 27(1):41-56.
    View on PubMed
  4. Deuker MM, Marsh Durban V, Phillips WA, McMahon M. PI3'-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma. Cancer Discov. 2015 Feb; 5(2):143-53.
    View on PubMed
  5. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer. 2014 Jul; 14(7):455-67.
    View on PubMed
  6. Deuker MM, McMahon M. Cancer biology: Enzyme meets a surprise target. Nature. 2014 Jun 12; 510(7504):225-6.
    View on PubMed
  7. Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
    View on PubMed
  8. Charles RP, Silva J, Iezza G, Phillips WA, McMahon M. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 2014 Jul; 12(7):979-86.
    View on PubMed
  9. Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DA. Isolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014 May 8; 7(3):645-53.
    View on PubMed
  10. McFadden DG, Vernon A, Santiago PM, Martinez-McFaline R, Bhutkar A, Crowley DM, McMahon M, Sadow PM, Jacks T. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):E1600-9.
    View on PubMed
  11. Juan J, Muraguchi T, Iezza G, Sears RC, McMahon M. Diminished WNT -> ß-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes Dev. 2014 Mar 15; 28(6):561-75.
    View on PubMed
  12. Silva JM, McMahon M. The fastest Western in town: a contemporary twist on the classic Western blot analysis. J Vis Exp. 2014; (84):e51149.
    View on PubMed
  13. Silva JM, Bulman C, McMahon M. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res. 2014 Mar; 12(3):447-63.
    View on PubMed
  14. Marsh Durban V, Deuker MM, Bosenberg MW, Phillips W, McMahon M. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J Clin Invest. 2013 Dec 2; 123(12):5104-18.
    View on PubMed
  15. Kamata T, Dankort D, Kang J, Giblett S, Pritchard CA, McMahon M, Leavitt AD. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res. 2013 Dec; 11(12):1530-41.
    View on PubMed
  16. Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B. Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci U S A. 2013 Nov 5; 110(45):18226-31.
    View on PubMed
  17. Goodwin AF, Tidyman WE, Jheon AH, Sharir A, Zheng X, Charles C, Fagin JA, McMahon M, Diekwisch TG, Ganss B, Rauen KA, Klein OD. Abnormal Ras signaling in Costello syndrome (CS) negatively regulates enamel formation. Hum Mol Genet. 2014 Feb 1; 23(3):682-92.
    View on PubMed
  18. Trejo CL, Green S, Marsh V, Collisson EA, Iezza G, Phillips WA, McMahon M. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res. 2013 Nov 1; 73(21):6448-61.
    View on PubMed
  19. Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, McMahon M, White E. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 2013 Nov; 3(11):1272-85.
    View on PubMed
  20. Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013 Feb 14; 494(7436):251-5.
    View on PubMed

Go to UCSF Profiles, powered by CTSI